

CURRICULUM VITAE

Sanjaya Saxena, M.D.

UCLA Neuropsychiatric Institute
300 UCLA Medical Plaza
Los Angeles, CA 90095
(310) 825-5938: office

California Medical License # G73437

Date of Birth: Feb. 2, 1964; Boston, MA

EDUCATION

Undergraduate:

Swarthmore College, Swarthmore, PA, 1981-1985.
B.A. with Distinction in Major, Psychology, June 1985.

Medical:

University of Minnesota Medical School, Minneapolis, MN, 1986-1990.
M.D. (Alpha Omega Alpha), June, 1990.

Internship:

UCLA Neuropsychiatric Institute / UCLA CHS / Wadsworth VA Medical Center, Los Angeles, CA,
June, 1990 - June, 1991. (Medicine, Psychiatry, and Neurology)

Psychiatry Residency:

UCLA Neuropsychiatric Institute, Los Angeles, CA, 1990 - 1994.
Chief Residency in Neuropsychiatry and Neurobehavior, UCLA / Brentwood VAMC,
July 1993 - June 1994.

Research Fellowship:

Charles A. Dana Foundation (Consortium on Neuroimaging Leadership Training) Scholarship:
Research on Neuroimaging in Neuropsychiatric Disorders, February, 1994 - December, 1995.
Research supervisors: Lewis R. Baxter, Jr., M.D., and Gary W. Small, M.D., UCLA Department of
Molecular and Medical Pharmacology and Department of Psychiatry and Biobehavioral Sciences.

BOARD CERTIFICATION

American Board of Psychiatry and Neurology, certified 1/96.

CURRENT PROFESSIONAL APPOINTMENTS

Associate Professor in Residence, UCLA Department of Psychiatry and Biobehavioral Sciences, July, 2002 - present.

Director, UCLA Obsessive-Compulsive Disorder Research Program, 1995 - present.

Associate Director, UCLA Anxiety Disorders Program, July, 1996 – present

PRIOR PROFESSIONAL APPOINTMENTS

Assistant Professor in Residence, UCLA Department of Psychiatry and Biobehavioral Sciences, January, 1996 - June, 2002

Assistant Research Neuropsychopharmacologist, UCLA Department of Medical and Molecular Pharmacology, July, 1994 - December, 1995.

Associate Physician Diplomate, UCLA Mental Health Group, July, 1994 - December, 1995.

Consulting Psychiatrist, Didi Hirsch Community Mental Health Clinic, 1992-1994.

HONORS AND AWARDS

Distinction in Major, Psychology, Swarthmore College, 6/85.

Sigma Xi Scientific Honor Society, inducted 4/85.

Alpha Omega Alpha, elected in Junior year, 2/89.

American Psychiatric Association/ Program for Minority Research Training Travel Award for the American College of Neuropsychopharmacology Annual Meeting, 12/93.

Travel Fellow for the West Coast College of Biological Psychiatry Annual Meeting, 4/95.

American Neuropsychiatric Association Young Investigator Award, 5/95.

Honorable Mention, APA/Smith Kline Beecham Young Faculty Award in Biological Psychiatry, 12/97.

American College of Neuropsychopharmacology, elected Associate Member 12/01.

Nominated for Faculty Housestaff Teaching Award, UCLA Department of Psychiatry and Biobehavioral Sciences, 2000-01, 2001-02, and 2003-04.

PROFESSIONAL ASSOCIATIONS

Alpha Omega Alpha
American College of Neuropsychopharmacology
American Society for Clinical Psychopharmacology
American Neuropsychiatric Association
American Psychiatric Association

National Alliance for the Mentally Ill
Obsessive-Compulsive Foundation - Member, Scientific Advisory Board
Obsessive-Compulsive & Spectrum Disorders Association - Chair, Scientific Advisory Board
Phi Chi Medical Society, President, 1989-1990
Sigma Xi Scientific Research Society

RESEARCH GRANTS

1. Obsessive Compulsive Foundation Research Grant
“Cerebral Metabolic Predictors of Response to Paroxetine and Risperidone in Refractory Obsessive-Compulsive Disorder”
Principal Investigator: Sanjaya Saxena, M.D.
Amount : \$ 19,600 Funding Period: 1/96 - 12/96.
2. NIMH RO1 MH53565-01A1
“Specific Brain System Mediation of Mood and Ritual”
Co- Principal Investigator
Principal Investigator: Lewis R. Baxter, Jr., M.D.
Amount: \$ 460,000 (Direct costs) Funding Period: 5/96 -4/99.
3. Solvay Pharmaceuticals
“Changes in the Quality of Life of People with OCD Following Treatment”
Principal Investigators: Karron Maidment, R.N. and Tanya Vapnik, M.A.
Co-Investigators and Supervisors: Sanjaya Saxena, M.D. and Alexander Bystritsky, M.D.
Amount: \$ 26,000 Funding Period: 7/96 - 7/01
4. Eli Lilly and Company
“Augmentation of SSRI Response in Refractory OCD Using Adjunctive Olanzapine”
Co-Investigator
Principal Investigator: Alexander Bystritsky, M.D.
Amount: \$58,000 Funding Period: 5/98 - 4/00
5. Obsessive Compulsive Foundation Research Grant
“Functional Neuroanatomy of Obsessive-Compulsive Hoarding”
Principal Investigator: Sanjaya Saxena, M.D.
Amount: \$19,000 Funding Period: 4/99 - 4/00
6. NIMH Mentored Patient-Oriented Research Career Development Award (K23 MH01694)
“Neuroanatomy and Pharmacotherapy of OCD and Major Depression”
Principal Investigator: Sanjaya Saxena, M.D.
Amount: \$843,708 (Total costs) Funding Period: 6/1/99 - 5/31/04
7. NIMH R01 MH069433-01A1 (pending)
"Neurobiology of Obsessive-Compulsive Hoarding"
Principal Investigator: Sanjaya Saxena, M.D.
Amount: \$2,346,231 (Total costs) Funding Period: 7/1/04 - 6/30/08

SCIENTIFIC PRESENTATIONS

1. Saxena S and Hartman BK. *Topographical organization of the cholinergic cells projecting from the laterodorsal tegmental (LDTg) and pedunculopontine tegmental (PPTg) nuclei to the thalamus in rat brain.* Poster presented at Society for Neuroscience Annual meeting, Phoenix, AZ, Oct. 30, 1989.
2. Frey WH, Weibenga ME, Emory CR, Saxena S, and Tollefson GD. *Alzheimer's and normal brains contain inhibitors of antagonist binding to the muscarinic acetylcholine receptor.* Presented at the Third International Conference on Alzheimer's Disease and Related Disorders, Padova Italy, July 12-17 1992.
3. Saxena S, Brody AL, Colgan ME, and Baxter LR. *PET Changes in OCD versus Depression with Paroxetine Treatment - Preliminary Data.* New Research Poster presented at American Psychiatric Association Annual Meeting, Philadelphia, PA, May, 1994.
4. Brody AL, Saxena S, Colgan ME, and Baxter LR. *Cerebral Metabolic Changes with Successful Paroxetine Treatment of Unipolar Depression versus Obsessive-Compulsive Disorder.* Poster presented at American College of Neuropsychopharmacology 33rd Annual Meeting, San Juan, Puerto Rico, December 13, 1994.
5. Saxena S, Brody AL, Colgan ME, and Baxter LR. *Cerebral Metabolic Changes with Successful Paroxetine Treatment of Obsessive-Compulsive Disorder versus Unipolar Depression.* Oral Presentation at West Coast College of Biological Psychiatry Annual Meeting, San Diego, CA, April 23, 1995.
6. Saxena S, Brody AL, Colgan ME, and Baxter LR. *Cerebral Metabolic Changes with Successful Paroxetine Treatment of Obsessive-Compulsive Disorder versus Unipolar Depression.* New Research Poster Presentation at American Neuropsychiatric Association Annual Meeting, Pittsburgh, PA, October 14, 1995.
7. Saxena S, Brody AL, Colgan ME, and Baxter LR. *PET Neuroimaging in Unipolar Depression and Obsessive-Compulsive Disorder: Effects of Treatment.* Poster presented at American College of Neuropsychopharmacology 34th Annual Meeting, December 11, 1995.
8. Saxena S. *PET Studies in Obsessive-Compulsive Disorder and Unipolar Depression..* Oral Presentation at 16th European Winter Conference on Brain Research, Serre-Chevalier, France, March 22, 1996.
9. Brody AL, Saxena S, Baxter LR, Schwartz JM, Stoessel P, and Maidment KM. *FDG-PET Predictors of Response to Cognitive-Behavioral Therapy versus Pharmacotherapy in Obsessive-Compulsive Disorder.* Poster presented at Society for Biological Psychiatry Annual Meeting, New York, NY, May 3, 1996.
10. Small GW, Saxena S, Barrio JR, Cole GM, La Rue A, Mandelkern MA, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD, and Phelps ME. *Strategies Using PET for Early Detection of Alzheimer's Disease.* Oral presentation at Society for Nuclear Medicine Annual Meeting, Denver, CO, June 5, 1996.
11. Baxter LR, Saxena S, Brody AL, Schwartz JM, and Ackermann RF. *Functional Neuroimaging Implications for Obsessive-Compulsive Disorder Neurosurgery.* Oral presentation at XXth CINP Congress, Melbourne, Australia, June 25, 1996.

12. Baxter LR, Brody AL, Saxena S, Schwartz JM, and Ackermann RF. *Specific Brain System Mediation in Obsessive-Compulsive Disorder Treatment*. Oral Presentation at XXth CINP Congress, Melbourne, Australia, June 27, 1996.
13. Brody AL, Saxena S, Schwartz JM, and Baxter LR. *Cerebral Metabolic Predictors of Response to Cognitive-Behavioral Therapy versus Fluoxetine in OCD*. Poster presented at American College of Neuropsychopharmacology 35th Annual Meeting, San Juan, Puerto Rico, December, 1996.
14. Schwartz JM, Brody AL, Saxena S, and Baxter LR. *Clinical and Imaging Predictors of Response to Cognitive-Behavioral Therapy*. Symposium at American Psychiatric Association Annual Meeting, San Diego, CA, May 20, 1997.
15. Bystritsky A, Saxena S, Maidment KM, Vapnik T, Rosen R, and Baxter LR: *Quality of Life Changes in Treatment-Resistant Obsessive-Compulsive Disorder*. Poster presented at American College of Neuropsychopharmacology 36th Annual Meeting, Kamuela, Hawaii, December, 1997.
16. Saxena S, Brody AL, Alborzian S, Maidment KM, Colgan ME, and Baxter LR. *Changes in Specific Subregions of Orbitofrontal Cortex with Successful Treatment of Obsessive-Compulsive Disorder*. Poster presented at American College of Neuropsychopharmacology 36th Annual Meeting, Kamuela, HI, December, 1997.
17. Brody AL, Saxena S, Alborzian S, Silverman DHS, Maidment K, Colgan ME, and Baxter LR. *Cerebral Metabolic Correlates of Changes in Depressive Symptom Clusters with Paroxetine Treatment*. Poster presented at American College of Neuropsychopharmacology 36th Annual Meeting, Kamuela, HI, December, 1997.
18. Saxena S, Brody AL, Alborzian S, Maidment KM, Colgan ME, and Baxter LR: *Localized Frontal and Subcortical Metabolic Changes with Successful Paroxetine Treatment of Obsessive-Compulsive Disorder*. Poster presented at American Neuropsychiatric Association Annual Meeting, Honolulu, HI, February 1, 1998.
19. Saxena S, Brody AL, and Baxter LR: *Functional Neuroanatomy and Cerebral Metabolic Predictors of Treatment Response in OCD*. Oral presentation at 3rd International OCD Conference, Madeira, Portugal, September 11, 1998.
20. Saxena S, Silverman DHS, Mega M, Levy M, Masterman D, Knox A, Ercoli L, Huang SC, Phelps ME, Cummings JL, and Small GW. *Effects of Donepezil Treatment on Cerebral Metabolism in Alzheimer's Disease: Preliminary Findings*. Poster presented at American College of Neuropsychopharmacology 37th Annual Meeting, Las Croabas, Puerto Rico, December 16, 1998.
21. Brody AL, Saxena S, Fairbanks L, Demaree HA, Maidment KM, and Baxter LR. *Personality Changes in Subjects Treated with Paroxetine*. Poster presented at American College of Neuropsychopharmacology 37th Annual Meeting, Las Croabas, Puerto Rico, December 16, 1998.
22. Small GW, Ercoli LM, Huang S-C, Komo S, Bookheimer SY, Saxena S, Silverman DHS, Mega MS, Mazziotta JC, Wu HM, Cummings JL, Phelps ME. *PET and Genetic Risk for Alzheimer Disease*. Presented at Society for Nuclear Medicine Annual Meeting, June, 1999.
23. Saxena S. *Novel and Theoretical Approaches to Pharmacotherapy for Refractory OCD*. Oral Presentation at 4th International OCD Conference, St. Thomas, U.S. Virgin Islands, Feb. 11, 2000.

24. Saxena S, Brody AL, Ho ML, Alborzian S, Phelps ME, & Baxter LR. *Cerebral metabolic abnormalities in major depression and obsessive-compulsive disorder occurring separately and concurrently*. Poster presented at American College of Neuropsychopharmacology 39th Annual Meeting, San Juan, Puerto Rico, December 11, 2000.
25. Bystritsky A, Ackermann DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, & Saxena S. *Augmentation of SSRI Response in Refractory OCD Using Adjunctive Olanzapine: A Placebo-Controlled Trial*. Poster presented at American College of Neuropsychopharmacology 39th Annual Meeting, San Juan, Puerto Rico, December 11, 2000.
26. Saxena S, Brody AL, Ho M, Alborzian S, Phelps ME, & Baxter LR: *Differential brain metabolic changes with paroxetine treatment of OCD vs. Major Depression occurring separately and concurrently*. Poster presented at American College of Neuropsychopharmacology 39th Annual Meeting, San Juan, Puerto Rico, December 13, 2000.
27. Saxena S & Bystritsky A. *Olanzapine Augmentation for SRI-Refractory OCD*. Oral Presentation at 5th International OCD Conference, Porto Cervo, Sardinia, Italy; March 30, 2001.
28. Bystritsky A, Ackermann DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, & Saxena S. *Augmentation of SSRI Response in Refractory OCD Using Adjunct Olanzapine: A Placebo-Controlled Trial*. Poster presented at 41st Annual NCDEU Meeting, June 12, 2001.
29. Baxter LR, Saxena S, & Brody AL. *Similar Basal Ganglia and Orbital Functional Changes with Drug or Behavioral Therapy of OCD Distinguish it from Depression*. Presentation at World Congress of Biological Psychiatry, Berlin, Germany, July 2, 2001.
30. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, & Baxter LR. *Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression*. Poster presented at American College of Neuropsychopharmacology 40th Annual Meeting, Kamuela, HI, December 9, 2001.
31. Saxena S. *Functional Neuroanatomy of OCD and Major Depression*. Oral presentation at West Coast College of Biological Psychiatry Annual Meeting, Santa Monica, CA, April 18, 2002.
32. Saxena S, Brody AL, Ho ML, Smith EC, Maidment KM, & Baxter LR. *Cerebral Metabolic Predictors of Response to Adjunctive Risperidone in Refractory Obsessive-Compulsive Disorder*. Poster presented at 42nd Annual NCDEU Meeting, Boca Raton, FL, June 11, 2002.
33. Saxena S, Maidment KM, Brody AL, Zohrabi N, Smith EC, & Baxter LR. *Neurobiology of Obsessive-Compulsive Hoarding*. Presentation at 9th Annual Obsessive-Compulsive Foundation Conference, Philadelphia, PA, August 10, 2002.
34. Saxena S. *Functional Neuroanatomy of Symptom Expression and Treatment Response in OCD*. Invited Presentation at American College of Neuropsychopharmacology 41st Annual Meeting, San Juan, Puerto Rico, December 9, 2002.
35. Saxena S, Brody AL, Ho ML, Smith EC, Maidment KM, & Baxter LR. *Cerebral Metabolic Predictors of Response to Adjunctive Risperidone in Refractory Obsessive-Compulsive Disorder*. Poster presentation at American College of Neuropsychopharmacology 41st Annual Meeting, San Juan, Puerto Rico, December 9, 2002.

36. Saxena S, Maidment KM, Smith EC, Zohrabi, N, Ho ML, Brody AL, & Baxter LR. *Functional Neuroanatomy of Obsessive-Compulsive Hoarding*. Poster presentation at American Neuropsychiatric Association 14th Annual Meeting, Honolulu, HI, February 4, 2003.

37. Saxena S. *Can Brain Imaging Untie the Anxiety/Depression Gordian Knot?* Oral presentation at International Society for Affective Disorders 2nd Biennial Conference, Cancun, Mexico, March 6, 2004.

INVITED LECTURES and COMMUNITY PRESENTATIONS

1. Saxena S, Brody AL, and Bystritsky A. *Treatment of OCD and Concomitant Conditions*. Workshop at Conference: OCD in the Family, Los Angeles, CA, July 1, 1995.
2. Saxena S. *Obsessive-Compulsive Disorder in Primary Care*. Valley Hospital Medical Center, Van Nuys, CA, September 14, 1995.
3. Saxena S. *Obsessive-Compulsive Disorder in Primary Care*. Downey Community Hospital, Downey, CA, January 12, 1996.
4. Saxena S. *Obsessive-Compulsive Spectrum Disorders*. Series of 10 lectures in Southern California, sponsored by Solvay Pharmaceuticals, April - December, 1996.
5. Saxena S. *Postpartum and Pregnancy-Related Obsessive-Compulsive Disorder*. Queen of Angels-Hollywood Presbyterian Hospital, Los Angeles, CA, May 13, 1996
6. Saxena S. *Obsessive-Compulsive Disorder*. UCLA Annual Review of Psychiatry, Los Angeles, CA, October 19, 1996.
7. Saxena, S. *Cross-Cultural Psychiatry: Treating Patients of Indian Heritage*. Psychiatry Grand Rounds, UCLA Neuropsychiatric Institute, Los Angeles, CA, May 27, 1997.
8. Saxena S. *Obsessive-Compulsive Spectrum Disorders*. Obsessive-Compulsive Foundation of California Conference, Los Angeles, CA, July 12, 1997.
9. Saxena S. *Obsessive-Compulsive Disorder and Tourette's Syndrome in Adults*. UCLA Second Annual Review of Psychiatry, Los Angeles, CA, October 25, 1997.
10. Saxena S. *Circuits and Symptoms: Functional Brain Imaging in OCD and Depression*. UCLA Department of Psychiatry Grand Rounds, Los Angeles, CA, January 13, 1998.
11. Saxena S. *Obsessive-Compulsive Spectrum Disorders*. Psychiatric Centers, San Diego, CA, March 6, 1998.
12. Saxena S. *Functional Neuroanatomy of Obsessive-Compulsive Disorder*. Psychiatry Grand Rounds, Olive View-UCLA Medical Center, Sylmar, CA, March 26, 1998.
13. Saxena S. *Clinical Overview of Obsessive-Compulsive Disorder*. Psychiatry Grand Rounds, Cedars-Sinai Hospital, Los Angeles, CA, July 9, 1998.

14. Saxena S. *Functional Brain Imaging and Psychopharmacology in OCD and Major Depression*. Encino-Tarzana Medical Center, Tarzana, CA, July 20, 1998.
15. Saxena S. *Obsessive-Compulsive Disorder in Adults: A Review and Update*. UCLA's Third Annual Review of Psychiatry, Los Angeles, CA, October 17, 1998.
16. Saxena S. *Obsessive-Compulsive Spectrum Disorders*. UCLA's Third Annual Review of Psychiatry, Los Angeles, CA, October 17, 1998.
17. Saxena S. *Circuits and Symptoms: Functional Brain Imaging in OCD and Depression*. Harbor-UCLA Medical Center, Torrance, CA, October 26, 1998.
18. Saxena S. *Obsessive-Compulsive Spectrum Disorders: Overview and Concepts*. Obsessive-Compulsive and Spectrum Disorders Association Conference, Los Angeles, CA, May 8, 1999.
19. Saxena S. *Pharmacotherapy and Neurobiology of OCD*. Obsessive-Compulsive and Spectrum Disorders Association Conference, Los Angeles, CA, May 8, 1999.
20. Saxena S. *Packrats, Clutterers, and Hoarders: The Diagnosis and Treatment of Obsessive-Compulsive Hoarding*. Obsessive-Compulsive and Spectrum Disorders Association Conference, Los Angeles, CA, May 8, 1999.
21. Saxena S. *Obsessive-Compulsive Disorder: Review and Update*. National Alliance for the Mentally Ill – South Bay Chapter, Torrance, CA, June 21, 1999.
22. Saxena S. *Obsessive-Compulsive Disorder in Primary Care*. Centinela Hospital Grand Rounds, Inglewood, CA, October 21, 1999.
23. Saxena S. *Treatment of Obsessive-Compulsive Disorder*. Kaiser San Fernando Valley, Reseda, CA, November 10, 1999.
3. Saxena S. *Circuits and Symptoms: The Functional Neuroanatomy of OCD and Major Depression*. UCLA's 2nd Annual Neuropsychiatry Today Conference, Indian Wells, CA, Feb. 5, 2000.
25. Saxena S. *Pharmacotherapy and Neurobiology of OCD in Adults*. Oral presentation at conference: Advances in the Treatment of OCD & Spectrum Disorders Across The Lifespan. Santa Monica, CA, April 29, 2000.
26. Saxena S. *Circuits and Symptoms: The Functional Neuroanatomy of OCD and Major Depression*. NIMH Intramural Branch, Mood and Anxiety Disorders Program, Feb. 28, 2001.
27. Saxena S. *The Functional Neuroanatomy of OCD*. Department of Neurology Grand Rounds, West Los Angeles VA Medical Center, Greater Los Angeles Veteran's Administration Healthcare System, July 20, 2001.
28. Saxena S. *OCD and Anxiety Disorders*. National Alliance for the Mentally Ill (NAMI) California Chapter Conference, Torrance, CA, Sept. 7, 2001.
29. Saxena S. *Circuits and Symptoms: The Functional Neuroanatomy of OCD and Major Depression*. Department of Psychiatry Grand Rounds, Stanford University School of Medicine, Palo Alto, CA, Jan. 24, 2002.

30. Saxena S. *Integrated Approaches to the Management of Obsessive-Compulsive Disorder*. UCLA's 4th Annual Neuropsychiatry Today Conference, Kaanapali, Maui, April 6, 2002.
31. Saxena S. *Psychotherapy, Pharmacotherapy, and Brain Function in Mood and Anxiety Disorders*. UCLA's 4th Annual Neuropsychiatry Today Conference, Kaanapali, Maui, April 7, 2002.
32. Bystritsky A and Saxena S. *Treatment-Resistant Obsessive-Compulsive Disorder*. UCLA Neuropsychiatric Institute, Los Angeles, CA, Jan. 16, 2003.
33. Saxena S. *Neurobiology of Obsessive-Compulsive Hoarding*. UCLA Neuropsychiatric Institute Grand Rounds, Los Angeles, CA, March 4, 2003.
34. Saxena S. *Neurobiology of Obsessive-Compulsive Hoarding*. Department of Psychiatry Grand Rounds, University of New Mexico Medical School, Albuquerque NM, March 7, 2003.
35. Saxena S. *Neurobiology of Obsessive-Compulsive Hoarding*. Department of Psychiatry Grand Rounds, University of California at San Diego School of Medicine, San Diego, CA, October 15, 2003.
36. Saxena S. *Neurobiology of Obsessive-Compulsive Hoarding*. Department of Psychiatry Grand Rounds, Stanford University, Palo Alto, CA, April 1, 2004.

PUBLISHED SCIENTIFIC ARTICLES

1. Tollefson GD, Zander J, Luxenburg M, Saxena S, Godes M, & Garvey MJ. Prediction of post-dexamethasone cortisol levels by serum sodium levels in patients with major depression. *Am J Psychiatry* 143: 81-84, 1986.
2. Tollefson GD, Luxenburg M, & Saxena S. A retrospective evaluation of plasma trazodone and clinical response in a primary care clinic. *Hillside J Clin Psychiatry* 10 (2): 183-7, 1989.
3. Saxena K & Saxena S. Scopolamine withdrawal syndrome. *Postgrad Med* 87: 23-26, 1990.
4. Frey WH, Emory CR, Weibenga ME, Saxena S, Cardelli D, Ala TA, & Tollefson GD. Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. *Brain Research* 655: 153-160, 1994.
5. Baxter LR, Saxena S, Brody AL, Ackermann RF, Colgan ME, Schwartz JM, Allen-Martinez Z, Fuster JM, & Phelps ME. Brain mediation of obsessive-compulsive disorder symptoms: evidence from functional brain imaging studies in the human and non-human primate. *Sem Clin Neuropsychiatry* 1: 32-46, 1996.
6. Saxena S, Wang D, Bystritsky A, and Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. *J Clin Psychiatry* 57: 303-306, 1996.
7. Brody AL and Saxena S. Brain imaging in obsessive-compulsive disorder: evidence for the involvement of frontal-subcortical circuitry in the mediation of symptomatology. *CNS Spectrums* 1: 27-41, 1996.

8. Small GW, Komo S, La Rue A, Saxena S, Phelps ME, Mazziota JC, Saunders AM, Haines JI, Pericak-Vance MA, & Roses AD. Early detection of Alzheimer Disease by combining apolipoprotein E and neuroimaging. *Ann NY Acad Sci.* 802: 10-78, 1996.
9. Saxena S, Brody AL, Schwartz JM, and Baxter LR. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. *Brit J Psychiatry* 173 (suppl. 35): 26-38, 1998.
10. Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, and Baxter LR. FDG-PET predictors of response to behavioral therapy versus pharmacotherapy in obsessive-compulsive disorder. *Psychiatry Res: Neuroimaging* 84: 1-6, 1998.
11. Bystritsky A, Saxena S, Maidment KM, Vapnik T, Tarlow G, and Rosen R. Quality-of-life changes among patients with obsessive-compulsive disorder in a partial hospitalization program. *Psychiatric Services* 50: 412-414, 1999.
12. Rauch SL, Benkelfat C, Dager S, Greenberg BD, Hendler T, Hollander E, Laruelle M, Rosenberg DR, Saxena S, Zohar J, & Baxter LR. Neuroimaging research and neurocircuitry models of obsessive-compulsive disorder: Proceedings of the Third IOCDC. *CNS Spectrums* 5 (suppl 3): 25-34, 1999.
13. Saxena S, Brody AL, Colgan ME, Maidment KM, Dunkin JJ, Alborzian S, Phelps ME, & Baxter LR. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment of obsessive-compulsive disorder. *Neuropsychopharmacology* 21: 683-693, 1999.
14. Small GW, Chen ST, Komo S, Ercoli L, Bookheimer SY, Miller K, Lavretsky H, Saxena S, Kaplan A, Dorsey D, Scott WK, Saunders AM, Haines JL, Roses AD, and Pericak-Vance MA. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E4 allele. *Am J Psychiatry* 156: 1035-1038, 1999.
15. Brody AL, Saxena S, Silverman DHS, Alborzian S, Fairbanks LA, Maidment KM, Phelps ME, and Baxter LR. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. *Psychiatry Res: Neuroimaging* 91: 127-139, 1999.
16. Brody AL, Saxena S, Fairbanks LA, Alborzian S, Demaree HA, Maidment KM, and Baxter LR. Personality changes in adult subjects with major depressive disorder or obsessive-compulsive disorder treated with paroxetine. *J Clin Psychiatry* 61: 349-355, 2000.
17. Small GW, Ercoli LM, Silverman DHS, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Mazziota JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, & Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's Disease. *Proc Nat Acad Sci USA* 97: 6037-6042, 2000.
18. Koran LM & Saxena S. Issues and strategies in treating refractory obsessive-compulsive disorder. *CNS Spectrums* 5 (suppl 4): 24-31, 2000.
19. Saxena S and Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. *Psychiatric Clin N Am* 23 (3): 563-586, 2000.
20. Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, and Bystritsky A. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder. *J Clin Psychiatry* 62: 67-72, 2001.

21. Saxena S, Bota RG, & Brody AL. Brain-behavior relationships in obsessive-compulsive disorder. *Sem Clin Neuropsychiatry* 6: 82-101, 2001.
22. Brody AL, Barsom M, Bota RG, & Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depression. *Sem Clin Neuropsychiatry* 6: 102-112, 2001.
23. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment KM, & Baxter LR. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy. *Arch Gen Psychiatry* 58: 631-640, 2001.
24. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, & Baxter LR. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. *Biol Psychiatry* 50: 159-170, 2001.
25. Brody AL, Saxena S, Mandelkern MA, Fairbanks LA, Ho ML, & Baxter LR. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. *Biol Psychiatry* 50: 171-178, 2001.
26. Small GW, Chen ST, Komo S, Ercoli L, Miller K, Siddarth P, Kaplan A, Dorsey D, Lavretsky H, Saxena S, Bookheimer SY. Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer's disease. *Int J Ger Psychiatry* 16: 1071-1077, 2001.
27. Bystritsky A, Liberman RP, Hwang S, Wallace CJ, Maidment KM, Vapnik T, & Saxena S. Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders. *Depression & Anxiety* 14: 214-218, 2001.
28. Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, Tarlow G, and Bystritsky A. Obsessive-compulsive hoarding: symptom severity and response to multi-modal treatment. *J Clin Psychiatry* 63: 21-27, 2002.
29. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, & Baxter LR. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder versus major depression. *Arch Gen Psychiatry* 59: 250-261, 2002.
30. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, & Zohar J. Refractory obsessive-compulsive disorder: State-of-the-art treatment. *J Clin Psychiatry* 63 (suppl 6): 20-29, 2002.
31. Hurley RA, Saxena S, Rauch SL, Hoehn-Saric R, Taber KH. Predicting treatment response in obsessive-compulsive disorder. *J Neuropsychiatry Clin Neurosci* 14: 249-253, 2002.
32. Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR, Madsen D, & Jarvik ME. Brain metabolic changes during cigarette craving. *Arch Gen Psychiatry* 59: 1162-1172, 2002.
33. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, & Baxter LR. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. *Am J Psychiatry* 160: 522-532, 2003.

34. Saxena S. The neurobiology and medication treatment of compulsive hoarding. *OCD Newsletter* 18 (1), Winter 2004.
35. Bystritsky A, Ackerman DL, Rosen R, Vapnik T, Gorbis E, Maidment KM, & Saxena S. Augmentation of SSRI response in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. *J Clin Psychiatry* 2004 (*accepted, in press*).
36. Saxena S, Brody AL, Maidment KM, Smith EC, Zohrabi N, Katz E, Baker SK, & Baxter LR. Cerebral glucose metabolism in obsessive-compulsive hoarding. *Am J Psychiatry* 161 (6), 2004 (*accepted, in press*).
37. Brody AL, Mandelkern MA, Lee GS, Smith EC, Sadeghi M, Saxena S, Jarvik ME, & London ED. Attenuation of cue-induced craving and anterior cingulate cortex activation in bupropion-treated smokers: A preliminary study. *Psychiatry Res: Neuroimaging* 2004 (*accepted, in press*).
38. Saxena S & Maidment KM. Treatment of obsessive-compulsive hoarding. *In Session: J Clin Psychology* 2004 (*accepted, in press*).
39. Saxena S, Brody AL, Smith EC, Ho ML, Zohrabi N, Katz E, Maidment M, & Baxter LR: Cerebral metabolic predictors of response to adjunctive risperidone in obsessive-compulsive disorder. *Biol Psychiatry* 2004 (*accepted, in press*).
40. Saxena S, Maidment KM, Tarlow G, Bystritsky A. Intensive cognitive-behavioral treatment of compulsive hoarding: A practical approach. (*submitted*)
41. Stoessel P, Maidment KM, Saxena S, Fairbanks L, Schwartz JM, Brody AL, Baxter LR. Psychotherapy pretreatment as augmentation for exposure and response prevention for patients with obsessive-compulsive disorder. (*manuscript in preparation*)
42. Saxena, S, Maidment KM, & Bystritsky A. Occupational impairment and quality of life in obsessive-compulsive hoarding. (*manuscript in preparation*)
43. Saxena S, Maidment KM, Dunkin JJ, & Bystritsky A. Prevalence of thyroid disorders in patients with obsessive-compulsive disorder versus mood disorders. (*manuscript in preparation*)
44. Matsui T, Saxena S, Katz E, Brody AL, & Baxter LR. Paralimbic cortical glucose metabolism in obsessive-compulsive disorder. (*manuscript in preparation*)
45. Saxena S, Brody AL, Sadeghi M, Katz E, & Baxter LR. Functional neuroimaging correlates of personality factors in OCD, major depression, and normal controls. (*manuscript in preparation*)
46. Saxena S, Mega M, Levy M, Ho ML, Ho MK, Smith EC, Ercoli L, Felix J, Kaplan A, Masterman DM, Small GW, & Cummings JL. Cerebral metabolic changes with donepezil treatment of Alzheimer's Disease. (*manuscript in preparation*)

PUBLISHED LETTERS AND BOOK CHAPTERS

1. Saxena S. Reply - Risperidone may worsen fluoxetine-treated OCD (letter). *J Clin Psychiatry* 59: 255, 1998.

2. Saxena S. Reply - Atypical antipsychotic-induced obsessive-compulsive symptoms (letter). *J Clin Psychiatry* 60: 262-263, 1999.
3. Baxter LR, Ackermann RF, Swerdlow NR, Brody AL, Saxena S, Schwartz JM, Gregoritch JM, Stoessel P, & Phelps ME. Specific brain system mediation of OCD responsive to either medication or behavior therapy. In *Obsessive-Compulsive Disorder: Contemporary Issues in Treatment*. Goodman W, Rudorfer M, Maser J, eds., Lawrence Erlbaum Associates, Inc., Mahwah, NJ, USA 2000, pp. 573-609.
4. Saxena S. Neuroimaging and the pathophysiology of obsessive-compulsive disorder. In: *Neuroimaging in Psychiatry*. Fu CHY, Senior C, Russell TA, Weinberger D, & Murray R, eds., Martin Dunitz, London 2003, p. 191-224.

PUBLISHED ABSTRACTS

1. Saxena S. & Hartman BK. Topographical organization of the cholinergic cells projecting from the laterodorsal tegmental (LDTg) and pedunculo-pontine tegmental (PPTg) nuclei to the thalamus in rat brain. *Society for Neuroscience Abstracts* 15(1): 834, 1989.
2. Saxena S, Brody A, Colgan M, and Baxter LR. Cerebral metabolic changes with successful paroxetine treatment of obsessive-compulsive disorder versus unipolar depression. *J Neuropsychiatry Clin Neurosci* 7 (3): 422, 1995.
3. Brody AL, Saxena S, Baxter LR, Schwartz JM, Stoessel P, and Maidment KM. FDG-PET Predictors of Response to Cognitive-Behavioral Therapy versus Pharmacotherapy in Obsessive-Compulsive Disorder. *Biol Psychiatry* suppl. 1996.
4. Small GW, Saxena S, Barrio JR, Cole GM, La Rue A, Mandelkern MA, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD, and Phelps ME. Strategies Using PET for Early Detection of Alzheimer's Disease. *J Nuc Med* 37(5): 307, 1996.
5. Saxena S, Brody AL, Alborzian S, Maidment KM, Colgan ME, and Baxter LR: Localized Frontal and Subcortical Metabolic Changes with Successful Paroxetine Treatment of Obsessive-Compulsive Disorder. *J Neuropsychiatry Clin Neurosci* 10; 1998.
6. Small GW, Ercoli LM, Huang S-C, Komo S, Bookheimer SY, Saxena S, Silverman DHS, Mega MS, Mazziotta JC, Wu HM, Cummings JL, Phelps ME. PET and Genetic Risk for Alzheimer Disease. Society for Nuclear Medicine Annual Meeting, 1999.
7. Baxter LR, Saxena S, & Brody AL. Similar Basal Ganglia and Orbital Functional Changes with Drug or Behavioral Therapy of OCD Distinguish it from Depression. *World J Biological Psychiatry*, 2001.
8. Saxena S, Maidment KM, Smith EC, Zohrabi, N, Ho ML, Brody AL, & Baxter LR. Functional Neuroanatomy of Obsessive-Compulsive Hoarding. *J Neuropsychiatry Clin Neurosci* 15 (2): 262-263, 2003.

EDITORIAL REVIEW SERVICE

Reviewer, *Journal of Clinical Psychiatry*, 1997-present
Reviewer, *Biological Psychiatry*, 1998-present
Reviewer, *Journal of Psychiatric Research*, 2000-present
Reviewer, *Psychiatric Research: Neuroimaging*, 2000-present
Reviewer, *American Journal of Geriatric Psychiatry*, 2001
Reviewer, *Psychiatric Research*, 2001
Reviewer, *CNS Spectrums*, 2001-present
Reviewer, *American Journal of Psychiatry*, 2001-present
Reviewer, *Archives of General Psychiatry*, 2003-present
Grant Reviewer, NIMH Intramural Research Program, 2003
Reviewer, *Neurology India*, 2003
Reviewer, *International Journal of Neuropsychopharmacology*, 2004

COMMITTEE SERVICE

Electroconvulsive Therapy Committee, UCLA Neuropsychiatric Hospital, 1997 - present.

Medical School Education Planning Committee, UCLA Neuropsychiatric Institute, 1998 - 2000.

Quality Assurance Committee, UCLA Neuropsychiatric and Behavioral Health Services, 1999 – present.

NPI Research Council, UCLA Neuropsychiatric Institute, 2000 - present.

Psychiatry Residency Curriculum Committee, UCLA Neuropsychiatric Institute, 2002 - present.

Child Psychiatry New Faculty Search Committee, UCLA Department of Psychiatry and Biobehavioral Sciences, 2003.

COMMUNITY ACTIVITIES

Member, Scientific Advisory Board, Obsessive-Compulsive Foundation, 2001 - present.

Chairman, Scientific Advisory Board for Obsessive-Compulsive and Spectrum Disorders Association, January, 1997 - 2001.

Psychiatric Consultant for motion picture, “As Good As It Gets,” Sony Pictures, 1997.